GlassScriptPhysician profile
George Zacharia
NPI 1285894121
$3,791.47
in general payments reported to CMS, 2019-2025
35 companies · $331 in 2025
The $331 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $524 · 2020: $197 · 2021: $167 · 2022: $831 · 2023: $856 · 2024: $884 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,002 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,001.80 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $478.60 | 2019-2025 | |
| Celgene Corporation | $274.76 | 2022-2025 | Reblozyl |
| Merck Sharp & Dohme LLC | $272.45 | 2019-2023 | Keytruda |
| Astrazeneca Pharmaceuticals LP | $264.11 | 2020-2024 | Lynparza, Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $256.86 | 2022-2025 | |
| Daiichi Sankyo INC. | $255.68 | 2020-2025 | Enhertu, Injectafer, Datroway |
| Genentech USA, INC. | $254.72 | 2019-2022 | |
| Pfizer INC. | $235.83 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $208.35 | 2019-2024 | Eliquis |
| Gilead Sciences, INC. | $191.28 | 2021-2024 | Trodelvy |
| Astellas Pharma US INC | $159.82 | 2019-2023 | Xtandi |
| Array Biopharma INC | $120.16 | 2024-2025 | Braftovi, Lorbrena, Mektovi |
| Pharmacyclics LLC, An Abbvie Company | $107.58 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $70.50 | 2021-2023 | Libtayo |
| Janssen Biotech, INC. | $68.84 | 2022-2024 | Darzalex, Akeega, Erleada |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $62.35 | 2024 | |
| Puma Biotechnology, INC. | $56.42 | 2020-2023 | |
| Abbvie INC. | $43.05 | 2024-2025 | |
| Eisai INC. | $40.36 | 2020-2022 | |
| Stemline Therapeutics INC. | $38.96 | 2023 | Orserdu |
| Teva Pharmaceuticals USA, INC. | $35.63 | 2019-2025 | Uzedy |
| Lilly USA, LLC | $33.51 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.15 | 2025 | Gilotrif |
| Blueprint Medicines Corporation | $24.47 | 2020 | |
| Amgen INC. | $23.50 | 2019 | |
| Recordati_rare_diseases_inc. | $22.27 | 2025 | Sylvant |
| Beigene USA, INC. | $21.94 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.95 | 2023 | Alunbrig |
| Seagen INC. | $18.65 | 2023 | Tukysa |
| Karyopharm Therapeutics INC. | $18.52 | 2023 | Xpovio |
| Mirati Therapeutics, INC. | $16.66 | 2023 | Krazati |
| Dendreon Pharmaceuticals LLC | $16.60 | 2025 | Provenge |
| Genzyme Corporation | $16.17 | 2022 | |
| Exelixis INC. | $15.03 | 2023 | Cabometyx |
| Amag Pharmaceuticals, INC. | $14.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Zacharia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.